Psychedelic Clinical Trials
Find clinical trials studying psilocybin, MDMA, ketamine and other psychedelics. Many trials are actively recruiting participants who haven't found relief from conventional treatments.
Integrating Ketamine Effects on Neuronal Molecular Signatures and the Brain Functional and Structural Connectome
Massachusetts General Hospital
Psilocybin-assisted Therapy for Alcohol Use Disorder
University of Sydney
Ketamine Treatment for PTSD and MDD in TBI
Minneapolis Veterans Affairs Medical Center
Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies
University of Washington
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
Cybin IRL Limited
Ketamine-assisted Integrative Treatment for Veterans With Chronic Low Back Pain and Comorbid Depression
VA Office of Research and Development
Ketamine for Pain, Opioid Use, and Mental Health in Orthopedic Trauma Patients
Texas Tech University Health Sciences Center
Psilocybin-Assisted Therapy for Intergenerational Trauma
Rachel Yehuda
Antidepressant Response of DMT Masked With Propofol
University Hospital, Basel, Switzerland
A Ketamine-assisted Group Therapy Intervention for Spanish-speaking Adults With Depression
Juliana Zambrano, MD, MPH
Ketamine Augmentation of ECT in Treatment-Resistant Depression
Università Vita-Salute San Raffaele
A Study of Ketamine Infusions to Treat Clinically-depressed ICU Patients
Mayo Clinic
Mood Effects of Serotonin Agonists: Depression
University of Chicago
A Randomized Neuroimaging Trial of Psilocybin in Depression
Sunnybrook Health Sciences Centre
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
M.D. Anderson Cancer Center
Retrospective Analyses of the Greenbrook Database Evaluating Mental Health Treatments
Neuronetics
Investigation to Understand and Optimize Psilocybin
Charles Raison
Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)
Centre for Addiction and Mental Health
Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND)
Centre for Addiction and Mental Health
Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans
Deepak C. D'Souza
Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder
Icahn School of Medicine at Mount Sinai
PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study
Yale University
Psilocybin rTMS for Treatment Resistant Depression
University of Texas at Austin
Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression
Icahn School of Medicine at Mount Sinai
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
Cybin IRL Limited
Veteran's Perceptions of Ketamine-Assisted Psychotherapy for Depression and End-of-Life
Albany Research Institute, Inc.
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
National Institute of Mental Health (NIMH)
Psilocybin for Treatment-Resistant Depression in Autism
Centre for Addiction and Mental Health
Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression
University Health Network, Toronto
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
Sharmin Ghaznavi
Imaging Depression in Parkinson's Disease
Yale University
The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
Dr. Inge Winter
Psilocybin Therapy for Depression in Parkinson's Disease
Joshua Woolley, MD, PhD
Lysergic Acid Diethylamide (LSD) in Palliative Care
University Hospital, Basel, Switzerland
Psilocybin for Hospitalized Patients with Treatment-resistant Depression
University Hospital, Ghent
Belief Updating in Treatment Resistant Depression
Assistance Publique - Hôpitaux de Paris
Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department
Lindsay Maguire, MD
Pharmacologic Treatment Augmentation in Chronic Depression
University Hospital Tuebingen
Psilocybin in Chronic Low Back Pain and Depression
Johns Hopkins University
Psilocybin-Assisted Therapy in Treatment-Resistant Depression
University of North Carolina, Chapel Hill
Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin
University Health Network, Toronto
Neural Circuit Effects of Ketamine in Depression
Icahn School of Medicine at Mount Sinai
i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial
University Health Network, Toronto
Two Doses of Psilocybin for the Treatment of MDD in Adults With Cancer
Sunstone Medical
RIVER At Home Ketamine Protocols
RIVER Foundation
The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects
Yale University
Metabolic Profiling of Esketamine Treatment in Depressive Disorder
University of Zagreb
IV Ketamine Vs. in Esketamine for MDD TRD
Gustavo Vazquez
Browse by Condition
View all conditions →How to Join a Clinical Trial
Clinical trials are research studies that test new treatments. Participating can give you access to cutting-edge therapies while contributing to medical science. Each trial has specific eligibility criteria based on the research goals.
1. Review
Read the trial details, eligibility criteria, and what participation involves.
2. Contact
Reach out to the study team using the contact information provided.
3. Screen
Complete the screening process to determine if you're eligible.